CCND2 and melanoma: MiR-182 over-expression was reported in melanoma in many studies, and it was suggested to act via converging onto forkhead box O3 (FOXO3), melanocyte inducing transcription factor (MITF), reversion inducing cysteine rich protein with Kazal motifs (RECK), BCL2 apoptosis regulator (BCL2), and CCND2 inactivation or via epigenetic modulation of human melanoma cells36–39.